Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 12/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20794207 | 1.00 | ADCY1 (0.52) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL22186645 | 1.00 | ADCY1 (0.52) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL20794206 | 1.00 | ADCY1 (0.52) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL9832504 | 0.87 | ADCY1 (0.41) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL21585135 | 0.86 | MAPK1 (0.40) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL24402196 | 0.85 | MAPK1 (0.47) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL6469176 | 0.83 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL21779505 | 0.83 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL11117898 | 0.83 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRSLC2A1 | |
| SCHEMBL12028527 | 0.83 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140314740-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF DIABETIC COMPLICATIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-23 | — | — | US | claimed |
| WO-2013086515-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF DIABETIC COMPLICATIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-13 | — | — | WO | claimed |
| WO-2009117769-A1 | INHIBITION OF C-KIT CANCERS | NEWCASTLE INNOVATION LIMITED (AU) | 2009-10-01 | — | — | WO | claimed |
| EP-1542663-B1 | A TREATMENT SOLUTION AND METHOD FOR PREVENTING POSTERIOR CAPSULAR OPACIFICATION BY SELECTIVELY INDUCING DETACHMENT AND/OR DEATH OF LENS EPITHELIAL CELLS | ZHANG JIN JUN (CN) | 2008-08-20 | — | — | EP | claimed |
| WO-2005120475-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BACTERIAL INFECTIONS AND SEPSIS | Technische Universität Dresden (DE) | 2005-12-22 | — | — | WO | claimed |
| JP-2002528411-A | — | — | 2002-09-03 | — | — | JP | claimed |
| US-20020037843-A1 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-03-28 | — | — | US | claimed |
| EP-1123090-A1 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-08-16 | — | — | EP | claimed |
| WO-2000024390-A9 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIV BRITISH COLUMBIA (CA) | 2000-12-07 | — | — | WO | claimed |
| WO-2000024390-A1 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-05-04 | — | — | WO | claimed |
| EP-0979086-A2 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-02-16 | — | — | EP | claimed |
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | claimed |
| EP-0879605-A2 | GLYCOSYL PRODRUG CONJUGATE WITH ENHANCED TOLERANCE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-25 | — | — | EP | claimed |
| WO-1998048784-A2 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1998-11-05 | — | — | WO | claimed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| EP-0647450-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-04-12 | — | — | EP | claimed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | claimed |
| EP-0595133-A2 | Prodrugs, their preparation and use as medicaments | BEHRINGWERKE Aktiengesellschaft (DE) | 1994-05-04 | — | — | EP | claimed |
| US-4724238-A | Method of treating inflammatory diseases with labdan derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-02-09 | — | — | US | claimed |
| US-12584111-B2 | Compositions and methods for long term culture of hepatocytes | PEKING UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4380965-A2 | PHARMACOLOGICAL AND/OR GENETIC ACTIVATOR FOR USE IN PRESERVING AND REGENERATING MUSCLE STRUCTURE AND FUNCTION BY BLOCKING SENESCENCE | Association Française contre les Myopathies (FR) | 2024-06-12 | — | — | EP | disclosed |
| US-20240108627-A1 | Phosphodiesterase Inhibitor Treatment | CYRANO THERAPEUTICS, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20230340415-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS | AMNIOTICS AB (SE) | 2023-10-26 | — | — | US | disclosed |
| WO-2023012264-A2 | PHARMACOLOGICAL AND/OR GENETIC ACTIVATOR FOR USE IN PRESERVING AND REGENERATING MUSCLE STRUCTURE AND FUNCTION BY BLOCKING SENESCENCE | ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (FR) | 2023-02-09 | — | — | WO | disclosed |
| US-11542473-B2 | Methods and compositions for generating hematopoietic cells | AMNIOTICS AB (SE) | 2023-01-03 | — | — | US | disclosed |
| WO-2022235021-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DRY EYE SYNDROME AND DRY EYE SYNDROME-RELATED OPHTHALMOLOGIC DISEASE | 연세대학교 산학협력단 | 2022-11-10 | — | — | WO | disclosed |
| US-20220226332-A1 | Phosphodiesterase Inhibitor Treatment | CYRANO THERAPEUTICS, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220135941-A1 | COMPOSITIONS AND METHODS FOR LONG TERM CULTURE OF HEPATOCYTES | PEKING UNIVERSITY (CN) | 2022-05-05 | — | — | US | disclosed |
| CN-113423818-A | Compositions and methods for long term culture of hepatocytes | 北京大学 | 2021-09-21 | — | — | CN | disclosed |
| US-10744141-B2 | Compositions and methods for treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-10683352-B1 | Methods for treating cancer using GRM8 inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200048609-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS | LONGBOAT AMNIOTICS AB (SE) | 2020-02-13 | — | — | US | disclosed |
| EP-2968204-B1 | PHOSPHODIESTERASE INHIBITORS FOR TREATING TASTE AND SMELL DISORDERS | HENKIN ROBERT I (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIV CASE WESTERN RESERVE (US) | 2019-04-25 | — | — | US | disclosed |
| US-10240173-B2 | Biosynthesis of forskolin and related compounds | UNIVERSITY OF COPENHAGEN (DK) | 2019-03-26 | — | — | US | disclosed |
| US-20190030036-A1 | PHOSPHODIESTERASE INHIBITOR TREATMENT | CYRANO THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20190010527-A1 | Biosynthesis of Forskolin and Related Compounds | DANSTAR FERMENT AG (CH) | 2019-01-10 | — | — | US | disclosed |
| US-10053717-B2 | Biosynthesis of forskolin and related compounds | UNIVERSITY OF COPENHAGEN (DK) | 2018-08-21 | — | — | US | disclosed |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | disclosed |
| EP-3313819-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Case Western Reserve University (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20180112243-A1 | BIOSYNTHESIS OF ACETYLATED 13R-MO AND RELATED COMPOUNDS | EVOLVA SA (CH) | 2018-04-26 | — | — | US | disclosed |
| WO-2018073615-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS | LONGBOAT EXPLORERS AB (SE) | 2018-04-26 | — | — | WO | disclosed |
| EP-3283623-A1 | BIOSYNTHESIS OF ACETYLATED 13R-MO AND RELATED COMPOUNDS | Evolva SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017176756-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2016210134-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160326557-A1 | Biosynthesis of Forskolin and Related Compounds | DANSTAR FERMENT AG (CH) | 2016-11-10 | — | — | US | disclosed |
| WO-2016166243-A1 | BIOSYNTHESIS OF ACETYLATED 13R-MO AND RELATED COMPOUNDS | EVOLVA SA (CH) | 2016-10-20 | — | — | WO | disclosed |
| US-9463210-B1 | Method for alleviating cravings and discomfort associated with smoking cessation8 | CAVALLARO ANTONINO (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160030435-A1 | PHOSPHODIESTERASE INHIBITOR TREATMENT | CYRANO THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9220706-B2 | Inhibition of leukemic stem cells by PP2A activating agents | NATIONAL INSTITUTES OF HEALTH (NIH) (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150141502-A1 | INHIBITION OF LEUKEMIC STEM CELLS BY PP2A ACTIVATING AGENTS | Ohio State Innvation Foundation (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140314740-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF DIABETIC COMPLICATIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140113962-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASE | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-04-24 | — | — | US | disclosed |
| US-8507219-B2 | Method of treating inflammation with statins | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2013086515-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF DIABETIC COMPLICATIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110237662-A1 | Use of Statins to Inhibit Inflammation and Vascular Disease | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-09-29 | — | — | US | disclosed |
| EP-0595133-B1 | Prodrugs, their preparation and use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-7838006-B2 | Viral vaccine composition, process and methods of use | IMMUNITOR USA INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100173832-A1 | ANTICANCEROUS POLYMERIC AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-07-08 | — | — | US | disclosed |
| US-7709454-B2 | Methods and compositions for inhibiting tumorigenesis | NEW YORK UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20100029613-A1 | TREATMENT AND PREVENTION OF EPILEPSY | UNIVERSITY OF ROCHESTER (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009117769-A1 | INHIBITION OF C-KIT CANCERS | NEWCASTLE INNOVATION LIMITED (AU) | 2009-10-01 | — | — | WO | disclosed |
| US-20090226489-A1 | VIRAL VACCINE COMPOSITION, PROCESS AND METHODS OF USE | IMMUNITOR USA INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090220432-A1 | Imaging agents and methods of using same for detecting multidrug resistance in cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090192120-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASE | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1976861-A2 | INHIBITING TUMOUR CELL INVASION, METASTASIS AND ANGIOGENESIS THROUGH TARGETTING LEGUMAIN | The Scripps Research Institute (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080226571-A1 | Compositions and methods to effect enhanced photoprotection against UV A and UV B induced damage of human skin | MAJEED MUHAMMED | 2008-09-18 | — | — | US | disclosed |
| US-7396659-B2 | Inhibitors of nitric oxide synthase to treat type 1 diabetes | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080152640-A1 | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2008-06-26 | — | — | US | disclosed |
| WO-2007064759-A2 | INHIBITING TUMOUR CELL INVASION, METASTASIS AND ANGIOGENESIS THROUGH TARGETTING LEGUMAIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007028141-A2 | IMAGING AGENTS AND METHODS OF USING SAME FOR DETECTING MULTIDRUG RESISTANCE IN CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070027094-A1 | Inhibitors of nitric oxide synthase | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070009530-A1 | Methods and compositions for inhibiting tumorigenesis | NEW YORK UNIVERSITY | 2007-01-11 | — | — | US | disclosed |
| US-7049058-B2 | Methods for suppressing the induction of nitric oxide synthase in a cell | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060035849-A1 | Methods and composition for modulating type I muscle formation using pgc-1 alpha | DANAFARBER CANCER INSTITUTE, INC (US) | 2006-02-16 | — | — | US | disclosed |
| EP-0795334-B1 | Prodrugs for the treatment tumors and inflammatory diseases | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1513558-A4 | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1alpha | DANA FARBER CANCER INST INC (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1513558-A2 | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1alpha | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-6830913-B1 | For diagnosis/therapy/drug screening; transportation of amyloids across membranes | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2004-12-14 | — | — | US | disclosed |
| US-20040235102-A1 | Novel ABCB9 transporter and uses thereof | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2004-11-25 | — | — | US | disclosed |
| WO-2003013537-A9 | IRINOTECAN FOR TREATMENT OF CANCER | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2004-04-29 | — | — | WO | disclosed |
| US-6660725-B1 | Method and composition for modulating amyloidosis | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2003-12-09 | — | — | US | disclosed |
| US-20030195256-A1 | Inhibitors of nitric oxide synthase | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2003-10-16 | — | — | US | disclosed |
| WO-2003068944-A2 | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α- | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| US-20030092145-A1 | Viral vaccine composition, process, and methods of use | IMMUNITOR USA INC. | 2003-05-15 | — | — | US | disclosed |
| US-20030027259-A1 | Novel ABCG4 transporter and uses thereof | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-02-06 | — | — | US | disclosed |
| US-6514686-B2 | Alzheimer's disease | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2003-02-04 | — | — | US | disclosed |
| US-6511800-B1 | Induction suppressor of a nitric oxide synthase or a cytokine; enzyme inhibitors | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2003-01-28 | — | — | US | disclosed |
| US-20020173004-A1 | Novel ABCA6 transporter and uses thereof | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-11-21 | — | — | US | disclosed |
| US-20020169137-A1 | Preventing or inhibiting pathological beta-amyloid plaque formation in conditions such as Alzheimer's disease | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-11-14 | — | — | US | disclosed |
| EP-1244703-A1 | NOVEL ABCB9 TRANSPORTER AND USES THEREOF | Activepass Pharmaceuticals, Inc. (CA) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002070692-A2 | ABCA9 TRANSPORTER AND USES THEREOF | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002070690-A2 | ABCA5 TRANSPORTER AND USES THEREOF | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002070693-A2 | NOVEL ABCA6 TRANSPORTER AND USES THEREOF | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002070691-A2 | ABCG4 TRANSPORTER AND USES THEREOF | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-09-12 | — | — | WO | disclosed |
| US-20020123106-A1 | Novel ABCA9 transporter and uses thereof | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-09-05 | — | — | US | disclosed |
| US-20020123107-A1 | Novel ABCA5 transporter and uses thereof | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-09-05 | — | — | US | disclosed |
| WO-2002064781-A2 | REGULATION OF AMYLOID PRECURSOR PROTEIN EXPRESSION BY MODIFICATION OF ABC TRANSPORTER EXPRESSION OR ACTIVITY | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-08-22 | — | — | WO | disclosed |
| EP-1210422-A2 | HUMAN ABC2 TRANSPORTER AND USES THEREOF | Active Pass Pharmaceuticals, Inc. (CA) | 2002-06-05 | — | — | EP | disclosed |
| US-20020037843-A1 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-03-28 | — | — | US | disclosed |
| EP-1123090-A1 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-08-16 | — | — | EP | disclosed |
| WO-2001040305-A1 | NOVEL ABCB9 TRANSPORTER AND USES THEREOF | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001014414-A2 | HUMAN ABC2 TRANSPORTER AND USES THEREOF | ACTIVEPASS PHARMACEUTICALS, INC. (CA) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000024390-A9 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIV BRITISH COLUMBIA (CA) | 2000-12-07 | — | — | WO | disclosed |
| US-6146658-A | ADMINISTERING A GLYCOSYL-SPACER-DRUG COMPOUND WHERE THE GLYCOSYL IS A SACCHARIDE WHICH CAN BE ENZYMATICALLY CLEAVED; DRUG IS ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE OR ANTITUMOR AGENT WHICH HYDROXYL OR AMINO GROUP; SELF-ELIMINATING SPACER | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-11-14 | — | — | US | disclosed |
| US-6107076-A | ACTIVATED BY G-PROTEIN, G-S-ALPHA; FOR SCREENING STIMULATORS AND ENZYME INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000024390-A1 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-05-04 | — | — | WO | disclosed |
| EP-0979086-A2 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-02-16 | — | — | EP | disclosed |
| US-6020315-A | Preparation having increased in vivo tolerability | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-01 | — | — | US | disclosed |
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | disclosed |
| US-5935995-A | POLY-, OLIGO- AND MONOSACCHARIDES OF DRUGS, E.G. NITROGEN MUSTARD GAS, QUININE AND DIPYRIDAMOLE; STABILITY; SLOW RELEASE; ANTIARTHITIC AGENTS; ENZYME INHIBITORS | HEOCHST AKTIENGESELLSCHAFT (DE) | 1999-08-10 | — | — | US | disclosed |
| WO-1999026657-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASE | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0879605-A2 | GLYCOSYL PRODRUG CONJUGATE WITH ENHANCED TOLERANCE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998048784-A2 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1998-11-05 | — | — | WO | disclosed |
| EP-0795334-A2 | Prodrugs for the treatment tumors and inflammatory diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-17 | — | — | EP | disclosed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | disclosed |
| EP-0647450-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-04-12 | — | — | EP | disclosed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | disclosed |
| US-5350864-A | Aminoalkylcarbamyl derivatives of forskolin as intermediates for the synthesis of useful forskolin derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-09-27 | — | — | US | disclosed |
| EP-0595133-A2 | Prodrugs, their preparation and use as medicaments | BEHRINGWERKE Aktiengesellschaft (DE) | 1994-05-04 | — | — | EP | disclosed |
| EP-0530252-A4 | AMINOALKYLCARBAMYL DERIVATIVES OF FORSKOLIN AS INTERMEDIATES FOR THE SYNTHESIS OF USEFUL FORSKOLIN DERIVATIVES | US HEALTH (US) | 1993-09-01 | — | — | EP | disclosed |
| EP-0530252-A1 | AMINOALKYLCARBAMYL DERIVATIVES OF FORSKOLIN AS INTERMEDIATES FOR THE SYNTHESIS OF USEFUL FORSKOLIN DERIVATIVES | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1993-03-10 | — | — | EP | disclosed |
| WO-1991017154-A1 | AMINOALKYLCARBAMYL DERIVATIVES OF FORSKOLIN AS INTERMEDIATES FOR THE SYNTHESIS OF USEFUL FORSKOLIN DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-11-14 | — | — | WO | disclosed |
| CN-87107118-A | Obtain the method for labdane type diterpene, particularly produce the method for forskolin by coleus forskohlii | — | 1988-06-15 | — | — | CN | disclosed |
| US-4751224-A | FORSKOLIN DERIVATIVES; ANTIAGGLOMERANTS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1988-06-14 | — | — | US | disclosed |
| US-4724238-A | Method of treating inflammatory diseases with labdan derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-02-09 | — | — | US | disclosed |
| EP-0167567-A1 | TREATMENT OF METASTASIS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1986-01-15 | — | — | EP | disclosed |
| WO-1985002616-A1 | TREATMENT OF METASTASIS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1985-06-20 | — | — | WO | disclosed |
| WO-1985002616-A1 | TREATMENT OF METASTASIS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1985-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175873-A1 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | ADCY1 1265/4885MAPK1 1568/4885CYP3A4 1633/4885 |
| US-20080152640-A1 | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer | ABCB1, ABCB11, SLC47A2 | ADCY1 2605/4885MAPK1 4234/4885CYP3A4 612/4885 |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | ADCY1 1265/4885MAPK1 1568/4885CYP3A4 1633/4885 |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PPP2CA, PPP3CA, PPP4C | ADCY1 2372/4885MAPK1 1293/4885CYP3A4 4796/4885 |
| US-10744141-B2 | Compositions and methods for treating cancer | PPP2CA, PPP3CA, PPP4C | ADCY1 2372/4885MAPK1 1293/4885CYP3A4 4796/4885 |
| US-12584111-B2 | Compositions and methods for long term culture of hepatocytes | WNT3A, CTNNB1, WNT1 | ADCY1 71/4885MAPK1 1469/4885CYP3A4 2641/4885 |
| US-20100173832-A1 | ANTICANCEROUS POLYMERIC AGENTS | ABCC1, ABCB1, SLC47A1 | ADCY1 4774/4885MAPK1 4020/4885CYP3A4 3603/4885 |
| US-20150141502-A1 | INHIBITION OF LEUKEMIC STEM CELLS BY PP2A ACTIVATING AGENTS | PPM1A, PPM1G, PPM1F | ADCY1 1015/4885MAPK1 255/4885CYP3A4 4633/4885 |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PARP2, PARP1, PPP2CA | ADCY1 2912/4885MAPK1 2987/4885CYP3A4 4287/4885 |
| US-20140314740-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF DIABETIC COMPLICATIONS | SLC2A1, SLC2A3, SLC2A2 | ADCY1 942/4885MAPK1 1518/4885CYP3A4 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.